Springer Science and Business Media LLC

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics
Springer Science and Business Media LLC - Tập 4 - Trang 1-17 - 2012
Alfonso Valencia, Manuel Hidalgo
Progress in genomics has raised expectations in many fields, and particularly in personalized cancer research. The new technologies available make it possible to combine information about potential disease markers, altered function and accessible drug targets, which, coupled with pathological and medical information, will help produce more appropriate clinical decisions. The accessibility of such experimental techniques makes it all the more necessary to improve and adapt computational strategies to the new challenges. This review focuses on the critical issues associated with the standard pipeline, which includes: DNA sequencing analysis; analysis of mutations in coding regions; the study of genome rearrangements; extrapolating information on mutations to the functional and signaling level; and predicting the effects of therapies using mouse tumor models. We describe the possibilities, limitations and future challenges of current bioinformatics strategies for each of these issues. Furthermore, we emphasize the need for the collaboration between the bioinformaticians who implement the software and use the data resources, the computational biologists who develop the analytical methods, and the clinicians, the systems' end users and those ultimately responsible for taking medical decisions. Finally, the different steps in cancer genome analysis are illustrated through examples of applications in cancer genome analysis.
Mass spectrometry for translational proteomics: progress and clinical implications
Springer Science and Business Media LLC - Tập 4 - Trang 1-11 - 2012
Erin Shammel Baker, Tao Liu, Vladislav A Petyuk, Kristin E Burnum-Johnson, Yehia M Ibrahim, Gordon A Anderson, Richard D Smith
The utility of mass spectrometry (MS)-based proteomic analyses and their clinical applications have been increasingly recognized over the past decade due to their high sensitivity, specificity and throughput. MS-based proteomic measurements have been used in a wide range of biological and biomedical investigations, including analysis of cellular responses and disease-specific post-translational modifications. These studies greatly enhance our understanding of the complex and dynamic nature of the proteome in biology and disease. Some MS techniques, such as those for targeted analysis, are being successfully applied for biomarker verification, whereas others, including global quantitative analysis (for example, for biomarker discovery), are more challenging and require further development. However, recent technological improvements in sample processing, instrumental platforms, data acquisition approaches and informatics capabilities continue to advance MS-based applications. Improving the detection of significant changes in proteins through these advances shows great promise for the discovery of improved biomarker candidates that can be verified pre-clinically using targeted measurements, and ultimately used in clinical studies - for example, for early disease diagnosis or as targets for drug development and therapeutic intervention. Here, we review the current state of MS-based proteomics with regard to its advantages and current limitations, and we highlight its translational applications in studies of protein biomarkers.
Obesity genomics: assessing the transferability of susceptibility loci across diverse populations
Springer Science and Business Media LLC - Tập 5 - Trang 1-14 - 2013
Yingchang Lu, Ruth JF Loos
The prevalence of obesity has nearly doubled worldwide over the past three decades, but substantial differences exist between nations. Although these differences are partly due to the degree of westernization, genetic factors also contribute. To date, little is known about whether the same genes contribute to obesity-susceptibility in populations of different ancestry. We review the transferability of obesity-susceptibility loci (identified by genome-wide association studies) using both single nucleotide polymorphism (SNP) and locus-wide comparisons. SNPs in FTO and near MC4R, obesity-susceptibility loci first identified in Europeans, replicate widely across other ancestries. SNP-to-SNP comparisons suggest that more than half of the 36 body mass index-associated loci are shared across European and East Asian ancestry populations, whereas locus-wide analyses suggest that the transferability might be even more extensive. Furthermore, by taking advantage of differences in haplotype structure, populations of different ancestries can help to narrow down loci, thereby pinpointing causal genes for functional follow-up. Larger-scale genetic association studies in ancestrally diverse populations will be needed for in-depth and locus-wide analyses aimed at determining, with greater confidence, the transferability of loci and allowing fine-mapping. Understanding similarities and differences in genetic susceptibility across populations of diverse ancestries might eventually contribute to a more targeted prevention and customized treatment of obesity.
Nghiên cứu đa chiều về dịch não tủy để khám phá và theo dõi phản ứng miễn dịch của hệ thần kinh trung ương Dịch bởi AI
Springer Science and Business Media LLC - Tập 14 - Trang 1-12 - 2022
Michael Heming, Anna-Lena Börsch, Heinz Wiendl, Gerd Meyer zu Hörste
Dịch não tủy (CSF) có thành phần tế bào miễn dịch độc đáo và luôn tiếp xúc với các ranh giới của não, do đó cho phép cung cấp thông tin về não nhằm chẩn đoán và theo dõi các bệnh lý. Gần đây, màng não, nơi chứa đựng CSF, được xác định là một giao diện thần kinh miễn dịch, làm nổi bật tiềm năng khám phá miễn dịch của hệ thần kinh trung ương (CNS) thông qua việc nghiên cứu các khu vực biên giới của hệ thần kinh trung ương. Ở đây, chúng tôi tóm tắt cách mà di truyền đơn bào của các khu vực biên này nâng cao hiểu biết của chúng tôi về các bệnh lý thần kinh, những thách thức còn tồn tại và các cơ hội mà các phương pháp đa omic mới mang lại. Các nghiên cứu di truyền đơn bào đã phát hiện ra các tế bào T CD4+ độc tế bào và các tế bào T và B khuếch đại dòng clone trong CSF ở bệnh tự miễn đa xơ cứng; các tế bào T CD8+ gây bệnh khuếch đại dòng clone được tìm thấy trong CSF và trong não gần các mảng β-amyloid của bệnh nhân sa sút trí tuệ; ở những bệnh nhân có di căn não, các kiểu clonotype tế bào T CD8+ được chia sẻ giữa mô não và CSF và vẫn tồn tại sau điều trị. Chúng tôi cũngnhấn mạnh cách mà các phương pháp đa omic mới cho phép đo đồng thời sự biểu hiện gen, khả năng tiếp cận cromatin, và protein trong cùng một tế bào, điều này vẫn cần được khám phá trong CSF. Điều này yêu cầu các sáng kiến đa trung tâm để tạo ra các bản đồ tế bào đơn bào, đặt ra thách thức trong việc tích hợp bệnh nhân và các phương pháp khác nhau giữa các trung tâm. Mặc dù các phân tích độ cao chiều của tế bào CSF là khó khăn, chúng có tiềm năng cho y học cá thể hóa bằng cách phân định tốt hơn các bệnh lý không đồng nhất và phân loại bệnh nhân.
#dịch não tủy #miễn dịch hệ thần kinh trung ương #tế bào đơn bào #bệnh thần kinh #đa xơ cứng
The circadian clock system’s influence in health and disease
Springer Science and Business Media LLC - Tập 9 - Trang 1-5 - 2017
Joseph T. Bass
Joseph T. Bass discusses recent developments in circadian clock research and reflects on the future of the field and its potential applications to clinical medicine.
Automated prioritization of sick newborns for whole genome sequencing using clinical natural language processing and machine learning
Springer Science and Business Media LLC - Tập 15 - Trang 1-9 - 2023
Bennet Peterson, Edgar Javier Hernandez, Charlotte Hobbs, Sabrina Malone Jenkins, Barry Moore, Edwin Rosales, Samuel Zoucha, Erica Sanford, Matthew N. Bainbridge, Erwin Frise, Albert Oriol, Luca Brunelli, Stephen F. Kingsmore, Mark Yandell
Rapidly and efficiently identifying critically ill infants for whole genome sequencing (WGS) is a costly and challenging task currently performed by scarce, highly trained experts and is a major bottleneck for application of WGS in the NICU. There is a dire need for automated means to prioritize patients for WGS. Institutional databases of electronic health records (EHRs) are logical starting points for identifying patients with undiagnosed Mendelian diseases. We have developed automated means to prioritize patients for rapid and whole genome sequencing (rWGS and WGS) directly from clinical notes. Our approach combines a clinical natural language processing (CNLP) workflow with a machine learning-based prioritization tool named Mendelian Phenotype Search Engine (MPSE). MPSE accurately and robustly identified NICU patients selected for WGS by clinical experts from Rady Children’s Hospital in San Diego (AUC 0.86) and the University of Utah (AUC 0.85). In addition to effectively identifying patients for WGS, MPSE scores also strongly prioritize diagnostic cases over non-diagnostic cases, with projected diagnostic yields exceeding 50% throughout the first and second quartiles of score-ranked patients. Our results indicate that an automated pipeline for selecting acutely ill infants in neonatal intensive care units (NICU) for WGS can meet or exceed diagnostic yields obtained through current selection procedures, which require time-consuming manual review of clinical notes and histories by specialized personnel.
Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination
Springer Science and Business Media LLC - Tập 16 - Trang 1-19 - 2024
Matthew R. Lawrence-Paul, Tien-chi Pan, Dhruv K. Pant, Natalie N. C. Shih, Yan Chen, George K. Belka, Michael Feldman, Angela DeMichele, Lewis A. Chodosh
Evolutionary models of breast cancer progression differ on the extent to which metastatic potential is pre-encoded within primary tumors. Although metastatic recurrences often harbor putative driver mutations that are not detected in their antecedent primary tumor using standard sequencing technologies, whether these mutations were acquired before or after dissemination remains unclear. To ascertain whether putative metastatic driver mutations initially deemed specific to the metastasis by whole exome sequencing were, in actuality, present within rare ancestral subclones of the primary tumors from which they arose, we employed error-controlled ultra-deep sequencing (UDS-UMI) coupled with FFPE artifact mitigation by uracil-DNA glycosylase (UDG) to assess the presence of 132 “metastasis-specific” mutations within antecedent primary tumors from 21 patients. Maximum mutation detection sensitivity was ~1% of primary tumor cells. A conceptual framework was developed to estimate relative likelihoods of alternative models of mutation acquisition. The ancestral primary tumor subclone responsible for seeding the metastasis was identified in 29% of patients, implicating several putative drivers in metastatic seeding including LRP5 A65V and PEAK1 K140Q. Despite this, 93% of metastasis-specific mutations in putative metastatic driver genes remained undetected within primary tumors, as did 96% of metastasis-specific mutations in known breast cancer drivers, including ERRB2 V777L, ESR1 D538G, and AKT1 D323H. Strikingly, even in those cases in which the rare ancestral subclone was identified, 87% of metastasis-specific putative driver mutations remained undetected. Modeling indicated that the sequential acquisition of multiple metastasis-specific driver or passenger mutations within the same rare subclonal lineage of the primary tumor was highly improbable. Our results strongly suggest that metastatic driver mutations are sequentially acquired and selected within the same clonal lineage both before, but more commonly after, dissemination from the primary tumor, and that these mutations are biologically consequential. Despite inherent limitations in sampling archival primary tumors, our findings indicate that tumor cells in most patients continue to undergo clinically relevant genomic evolution after their dissemination from the primary tumor. This provides further evidence that metastatic recurrence is a multi-step, mutation-driven process that extends beyond primary tumor dissemination and underscores the importance of longitudinal tumor assessment to help guide clinical decisions.
Erratum to: Colorectal cancer screening: will non-invasive procedures triumph?
Springer Science and Business Media LLC - Tập 7 - Trang 1-1 - 2015
Timothy Church
Clinical trial design in the era of precision medicine
Springer Science and Business Media LLC - Tập 14 - Trang 1-27 - 2022
Elena Fountzilas, Apostolia M. Tsimberidou, Henry Hiep Vo, Razelle Kurzrock
Recent rapid biotechnological breakthroughs have led to the identification of complex and unique molecular features that drive malignancies. Precision medicine has exploited next-generation sequencing and matched targeted therapy/immunotherapy deployment to successfully transform the outlook for several fatal cancers. Tumor and liquid biopsy genomic profiling and transcriptomic, immunomic, and proteomic interrogation can now all be leveraged to optimize therapy. Multiple new trial designs, including basket and umbrella trials, master platform trials, and N-of-1 patient-centric studies, are beginning to supplant standard phase I, II, and III protocols, allowing for accelerated drug evaluation and approval and molecular-based individualized treatment. Furthermore, real-world data, as well as exploitation of digital apps and structured observational registries, and the utilization of machine learning and/or artificial intelligence, may further accelerate knowledge acquisition. Overall, clinical trials have evolved, shifting from tumor type-centered to gene-directed and histology-agnostic trials, with innovative adaptive designs and personalized combination treatment strategies tailored to individual biomarker profiles. Some, but not all, novel trials now demonstrate that matched therapy correlates with superior outcomes compared to non-matched therapy across tumor types and in specific cancers. To further improve the precision medicine paradigm, the strategy of matching drugs to patients based on molecular features should be implemented earlier in the disease course, and cancers should have comprehensive multi-omic (genomics, transcriptomics, proteomics, immunomic) tumor profiling. To overcome cancer complexity, moving from drug-centric to patient-centric individualized combination therapy is critical. This review focuses on the design, advantages, limitations, and challenges of a spectrum of clinical trial designs in the era of precision oncology.
Modeling psychiatric disorders using patient stem cell-derived neurons: a way forward
Springer Science and Business Media LLC - Tập 10 - Trang 1-3 - 2018
Krishna C. Vadodaria, Debha N. Amatya, Maria C. Marchetto, Fred H. Gage
Our understanding of the neurobiology of psychiatric disorders remains limited, and biomarker-based clinical management is yet to be developed. Induced pluripotent stem cell (iPSC) technology has revolutionized our capacity to generate patient-derived neurons to model psychiatric disorders. Here, we highlight advantages and caveats of iPSC disease modeling and outline strategies for addressing current challenges.
Tổng số: 1,249   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10